Kantarjian H - Search Results

1

New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia.

Badar T, Luthra R, Kantarjian H, Jabbour E, Borthakur G, Garcia-Manero G, Huang X, Singh R, Alvarez B, Austermiller B, Morrison TB, Patel KP, Cortes J. Badar T, et al. Among authors: kantarjian h. Appl Immunohistochem Mol Morphol. 2019 Jan;27(1):33-39. doi: 10.1097/PAI.0000000000000526. Appl Immunohistochem Mol Morphol. 2019. PMID: 28682832

2

Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy.

Lee MS, Kantarjian H, Talpaz M, Freireich EJ, Deisseroth A, Trujillo JM, Stass SA. Lee MS, et al. Among authors: kantarjian h. Blood. 1992 Apr 15;79(8):1920-3. Blood. 1992. PMID: 1562719 Free article.

3

Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction.

Dhingra K, Kurzrock R, Kantarjian H, Baine R, Eastman PS, Ku S, Gutterman JU, Talpaz M. Dhingra K, et al. Among authors: kantarjian h. Leukemia. 1992 Aug;6(8):754-60. Leukemia. 1992. PMID: 1640725

4

Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression.

Dhingra K, Talpaz M, Kantarjian H, Ku S, Rothberg J, Gutterman JU, Kurzrock R. Dhingra K, et al. Among authors: kantarjian h. Leukemia. 1991 Mar;5(3):191-5. Leukemia. 1991. PMID: 2013978

5

A phosphatase activity present in peripheral blood myeloid cells of chronic myelogenous leukemia patients but not normal individuals alters nuclear protein binding to transcriptional enhancers of interferon-inducible genes.

Seong DC, Sims S, Johnson E, Howard OM, Reiter B, Hester J, Talpaz M, Kantarjian H, Deisseroth A. Seong DC, et al. Among authors: kantarjian h. J Clin Invest. 1990 Nov;86(5):1664-70. doi: 10.1172/JCI114889. J Clin Invest. 1990. PMID: 2243138 Free PMC article.

6

Lack of breakpoint cluster region rearrangement in marrow fibroblasts of patients with Philadelphia chromosome-positive chronic myelogenous leukemia.

O'Brien S, Kantarjian H, Shtalrid M, Blick M, Beran M, Talpaz M. O'Brien S, et al. Among authors: kantarjian h. Hematol Pathol. 1988;2(1):25-9. Hematol Pathol. 1988. PMID: 3235381

7

Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes.

Cortes JE, Kantarjian H, O'Brien S, Keating M, Pierce S, Freireich EJ, Estey E. Cortes JE, et al. Among authors: kantarjian h. Leukemia. 1995 Jan;9(1):115-7. Leukemia. 1995. PMID: 7845005

8

Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.

Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R. Talpaz M, et al. Among authors: kantarjian h. J Clin Invest. 1994 Oct;94(4):1383-9. doi: 10.1172/JCI117473. J Clin Invest. 1994. PMID: 7929813 Free PMC article.

9

What is the contribution of molecular studies to the diagnosis of BCR-ABL-positive disease in adult acute leukemia?

Kantarjian H, Talpaz M, Estey E, Ku S, Kurzrock R. Kantarjian H, et al. Am J Med. 1994 Feb;96(2):133-8. doi: 10.1016/0002-9343(94)90133-3. Am J Med. 1994. PMID: 8109597

10

All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia.

Cortes JE, Kantarjian H, O'Brien S, Robertson LE, Koller C, Hirsh-Ginsberg C, Stass S, Keating M, Estey E. Cortes JE, et al. Among authors: kantarjian h. Cancer. 1994 Jun 15;73(12):2946-52. doi: 10.1002/1097-0142(19940615)73:12<2946::aid-cncr2820731211>3.0.co;2-q. Cancer. 1994. PMID: 8199992 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,507 results

Search Page